Searched for
SPECIALTY PHARMACEUTICAL FIRM
Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Anupam Rasayan becomes world's first to make ETFA using flow chemistryAnupam Rasayan India Ltd has achieved a global first by commercialising Ethyl trifluoroacetate production using its unique continuous flow ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...
- Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 crSpecialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with a...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Carlyle buys RCM providers Knack & Equalize for $600 millionCarlyle Group is building a global healthcare revenue cycle management platform. The firm acquired majority stakes in US companies Knack an...
- Carlyle acquires Knack RCM and Equalize RCM to create an AI-native, global multi-specialty healthcare RCM platformGlobal investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM....
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Promoters Buying: 9 Nifty 500 stocks that saw stake hikes in March quarterPromoters are showing increased confidence in several Nifty 500 companies. Their shareholding has risen in the March 2026 quarter compared ...
- India to attract major share of EQT's $15.6-billion Asia fund: EQT India headEQT expects India to remain a top capital destination in its new Asia fund, with roughly one-third allocation historically. The firm sees s...
- Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitisGlenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray...
- Glenmark looks to file up to 25 product applications annuallyWe expect to file 20-25 abbreviated new drug applications each year over the next 5 years and launch 10-20 products annually," Glenmark MD ...
- Themis Medicare inks pact with Nevakar for injectable productsThe New Jersey-based specialty pharmaceutical firm Navakar has expertise in commercialising pharma products in the US as well as global mar...
- Glenmark working on proprietary product rolloutThe company plans to build a global manufacturing footprint, increase presence in complex generics, launching of specialty business in the ...
- Lupin on buying spree; to acquire German company Temmler Pharma's product portfolioA day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...
Load More
